Skip to main content
. 2019 May 23;90(9):1059–1067. doi: 10.1136/jnnp-2018-319190

Figure 3.

Figure 3

(A) RRMS in remission versus controls (NINDCs) and (b) RRMS in relapse versus controls (HCs and NINDCs), subgroup and combined meta-analysis. (a) CSF NfL levels were higher in patients with RRMS in remission than disease controls, with a moderate effect size of 0.67; (b) CSF NfL levels were higher in patients with RRMS in relapse than both healthy and disease controls, with a large effect size of 1.13; however, heterogeneity between studies was also significant. CSF, cerebrospinal fluid; HCs, healthy controls; NfL, neurofilament light chain; MS, multiple sclerosis; NINDCs, non-inflammatory neurological disease controls; RRMS, relapsing remitting MS; SMD, standard mean deviation.